Table 3.
Event rates by DOPPS phase and region
| N patients | All-cause mortality |
MACE |
MACE+ |
||||
|---|---|---|---|---|---|---|---|
| N events | Rate (95% CI) | N events | Rate (95% CI) | N events | Rate (95% CI) | ||
| North America | |||||||
| Phase 4 (2009−2011) | 2256 | 388 | 14.3 (13.0–15.8) | 466 | 17.7 (16.2–19.4) | 520 | 20.2 (18.6–22.1) |
| Phase 5 (2012−2015) | 1637 | 317 | 13.5 (12.1–15.1) | 377 | 16.6 (15.0–18.3) | 412 | 18.4 (16.8–20.3) |
| Europe | |||||||
| Phase 4 (2009−2011) | 5240 | 1032 | 13.2 (12.4–14.1) | 1198 | 15.8 (14.9–16.7) | 1300 | 17.5 (16.5–18.4) |
| Phase 5 (2012−2015) | 3506 | 644 | 13.1 (12.1–14.2) | 740 | 15.4 (14.3–16.5) | 813 | 17.2 (16.1–18.4) |
| Japan | |||||||
| Phase 4 (2009−2011) | 2001 | 204 | 4.8 (4.2–5.6) | 256 | 6.2 (5.5–7.0) | 283 | 6.9 (6.1–7.7) |
| Phase 5 (2012−2015) | 1920 | 208 | 6.0 (5.3–6.9) | 255 | 7.5 (6.7–8.5) | 273 | 8.1 (7.2–9.2) |
CI, confidence interval; DOPPS, Dialysis Outcomes and Practice Patterns Study; MACE, major adverse cardiovascular events; MACE+, MACE plus heart failure and thromboembolic events; non-VA, nonvascular access.
MACE includes all-cause mortality plus hospitalization due to myocardial infarction or stroke. MACE+ includes MACE plus heart failure and thromboembolic events (non-VA). Rates expressed per 100 patient-years.